Avalo Therapeutics Inc (AVTX)
14.36
-1.03
(-6.69%)
USD |
NASDAQ |
May 03, 16:00
14.20
-0.16
(-1.11%)
Pre-Market: 20:00
Avalo Therapeutics Research and Development Expense (Quarterly): 1.867M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.867M |
| September 30, 2023 | 1.249M |
| June 30, 2023 | 4.658M |
| March 31, 2023 | 6.008M |
| December 31, 2022 | 6.172M |
| September 30, 2022 | 7.042M |
| June 30, 2022 | 8.51M |
| March 31, 2022 | 9.584M |
| December 31, 2021 | 11.51M |
| September 30, 2021 | 10.55M |
| June 30, 2021 | 12.57M |
| March 31, 2021 | 25.21M |
| December 31, 2020 | 12.64M |
| September 30, 2020 | 8.872M |
| June 30, 2020 | 5.917M |
| March 31, 2020 | 4.768M |
| December 31, 2019 | 2.907M |
| September 30, 2019 | 1.743M |
| June 30, 2019 | 3.713M |
| March 31, 2019 | 3.401M |
| Date | Value |
|---|---|
| December 31, 2018 | 2.006M |
| September 30, 2018 | 1.048M |
| June 30, 2018 | 1.083M |
| March 31, 2018 | 1.650M |
| December 31, 2017 | 1.961M |
| September 30, 2017 | 0.9646M |
| June 30, 2017 | 0.4936M |
| March 31, 2017 | 0.9531M |
| December 31, 2016 | 0.7732M |
| September 30, 2016 | 4.582M |
| June 30, 2016 | 2.502M |
| March 31, 2016 | 2.293M |
| December 31, 2015 | 1.751M |
| September 30, 2015 | 1.237M |
| June 30, 2015 | 1.875M |
| March 31, 2015 | 1.723M |
| December 31, 2014 | 2.259M |
| September 30, 2014 | 4.371M |
| June 30, 2014 | 2.861M |
| March 31, 2014 | 2.750M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.249M
Minimum
Sep 2023
25.21M
Maximum
Mar 2021
7.657M
Average
6.172M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Imunon Inc | 3.553M |
| iBio Inc | 1.535M |
| Kodiak Sciences Inc | 46.63M |
| Petros Pharmaceuticals Inc | 0.8343M |
| Ocugen Inc | 9.504M |